5.90

2.25% 0.13

Abeona Therapeutics Inc (ABEO)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Abeona Therapeutics Inc stock is traded at $5.90, with a volume of 852.65K. It is up +2.25% in the last 24 hours and up +21.15% over the past month. Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.

Previous Close:

$5.77

Open:

$5.81

24h Volume:

852.65K

Relative Volume:

0.72

Market Cap:

$335.61M

Revenue:

$5.82M

Net Income/Loss:

$71.18M

P/E Ratio:

5.9166

EPS:

0.9972

Net Cash Flow:

$-84.30M

1W Performance:

+8.66%

1M Performance:

+21.15%

6M Performance:

+40.48%

1Y Performance:

+7.47%

1-Day Range:

$5.74

$5.96

1-Week Range:

$5.42

$6.07

52-Week Range:

$4.00

$7.5401

Abeona Therapeutics Inc Stock (ABEO) Company Profile

Name

Abeona Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

646-813-4701

Address

6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY

Employee

226

Twitter

@abeonabio

Next Earnings Date

2026-05-13

Latest SEC Filings

ABEO's Discussions on Twitter

Compare ABEO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABEO Abeona Therapeutics Inc	5.90	335.61M	5.82M	71.18M	-84.30M	0.9972
VRTX Vertex Pharmaceuticals Inc	429.82	109.09B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	714.89	74.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	782.17	48.64B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.05	39.39B	4.29B	577.22M	641.34M	4.2086
ONC Beone Medicines Ltd Adr	312.12	32.38B	5.36B	287.73M	924.18M	2.5229

Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-02-25	Resumed	Oppenheimer	Outperform
Mar-05-25	Initiated	Oppenheimer	Outperform
Jul-03-24	Initiated	H.C. Wainwright	Buy
May-30-24	Initiated	Stifel	Buy
Nov-11-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Sep-18-20	Initiated	B. Riley FBR	Buy
Feb-10-20	Initiated	SVB Leerink	Outperform
Dec-10-19	Resumed	Cantor Fitzgerald	Neutral
Aug-15-19	Downgrade	Maxim Group	Buy → Hold
Aug-12-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jul-26-19	Downgrade	Mizuho	Buy → Neutral
Jun-27-19	Initiated	Mizuho	Buy
Oct-12-18	Initiated	Mizuho	Buy
Jun-05-18	Initiated	Seaport Global Securities	Buy
Nov-08-17	Initiated	SunTrust	Buy
Oct-16-17	Reiterated	H.C. Wainwright	Buy
Oct-11-17	Reiterated	Cantor Fitzgerald	Overweight
Oct-10-17	Initiated	Citigroup	Buy
Oct-05-17	Reiterated	Maxim Group	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Jul-18-17	Reiterated	Maxim Group	Buy
Jun-22-17	Resumed	Jefferies	Buy
Jan-06-17	Initiated	Jefferies	Buy
Sep-29-16	Reiterated	Maxim Group	Buy

View All

Abeona Therapeutics Inc Stock (ABEO) Latest News

01:32 AM

Abeona Therapeutics® Announces Date of First Quarter Financial Results - The Manila Times

May 04, 2026

Abeona sets May 13 investor call on Q1 results and company progress - Stock Titan

May 04, 2026

May 02, 2026

2,000,000 Shares in Abeona Therapeutics Inc. $ABEO Purchased by AIGH Capital Management LLC - MarketBeat

May 02, 2026

May 01, 2026

Eight new Abeona hires get stock awards that vest over 3 years - Stock Titan

May 01, 2026

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ChartMill

May 01, 2026

Apr 28, 2026

AIGH, Orin Hirschman disclose 3.1M ABEO shares (ABEO) - Stock Titan

Apr 28, 2026

Abeona Therapeutics (NASDAQ:ABEO) Share Price Crosses Above 50 Day Moving AverageHere's What Happened - MarketBeat

Apr 28, 2026

Apr 27, 2026

[ARS] ABEONA THERAPEUTICS INC. SEC Filing - Stock Titan

Apr 27, 2026

Abeona Therapeutics (NASDAQ: ABEO) sets 2026 virtual meeting on directors, pay and equity plan - Stock Titan

Apr 27, 2026

Apr 26, 2026

(ABEO) Risk Channels and Responsive Allocation - Stock Traders Daily

Apr 26, 2026

Apr 23, 2026

Abeona (ABEO) Competitive Advantages | Abeona Therapeutics 2% EPS miss, $5.82M revenueRevenue Growth Rate - Xã Vĩnh Công

Apr 23, 2026

ABEO Should I Buy - Intellectia AI

Apr 23, 2026

Apr 21, 2026

Spotlighting Abeona Therapeutics And 2 More High Growth Stocks Insiders Favor - Yahoo Finance

Apr 21, 2026

Abeona Therapeutics Inc. (NASDAQ:ABEO) Q4 2025 earnings call transcript - MSN

Apr 21, 2026

Apr 17, 2026

Abeona Therapeutics (NASDAQ: ABEO) asks shareholders to approve 3.1M extra equity shares - Stock Titan

Apr 17, 2026

Apr 16, 2026